Nkarta (NKTX) said Thursday it opened enrollment for the Ntrust-2 trial and received clearance to initiate an investigator-sponsored trial to evaluate its experimental therapy, NKX019, in patients with myasthenia gravis.
The company said Ntrust-2 is a study to assess NKX019 in patients with systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis.
The investigator-sponsored study would be led by researchers at the University of California, Irvine, and the University of Kansas Medical Center, the company said.
It added the trials will evaluate the therapy's safety and potential to induce long-term remission by eliminating pathogenic B cells.
Preliminary data from the studies are expected in 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。